Altimmune, Inc.

As of June 30, 2026, Altimmune, Inc. carries a market capitalization of 10.50B, placing it among publicly traded companies globally. Its enterprise value stands at 5.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Altimmune, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Altimmune, Inc. has 194.47M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 12,461.05, and the price-to-book ratio stands at 1.27.

These figures are as of June 30, 2026. The EV/Sales ratio of 10,026.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.43B versus a market cap of 10.50B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Altimmune, Inc. maintains a current ratio of 26.78, meaning it holds 26.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.60, indicating elevated leverage, while an interest coverage ratio of -28.32 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Altimmune, Inc. posted a negative return on equity (ROE) of -28.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.58, reflecting losses generated across the asset base. The company generates approximately 9,419.47 in revenue per employee across its workforce of 57.50, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Altimmune, Inc.'s stock has declined approximately 43.67% over the past 52 weeks. The 50-day moving average sits at 50.64, while the 200-day moving average is 94.56.

Over the twelve months ended June 30, 2026, Altimmune, Inc. generated 541,619.60 in revenue and converted that into -1.60B in net income, yielding earnings per share of -12.83. EBITDA reached -1.75B, while operating income came in at -1.75B.

As of June 30, 2026, Altimmune, Inc. holds 5.70B in cash and equivalents against 629.33M in total debt, resulting in a net debt position of -493.85M. Total book value stands at 8.29B, with working capital of 5.63B providing operational flexibility.

Altimmune, Inc. produced -1.34B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -943,466.40 in capital expenditures, free cash flow totaled -1.34B - equivalent to -10.70 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -323,306.45 and net profit margin of -296,000.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -68.22, meaning Altimmune, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Altimmune, Inc.'s most recent stock split took place on September 14, 2018 with a 30:1 split ratio.

As of June 30, 2026, Altimmune, Inc. has an Altman Z-Score of 5.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.